The startup specializes in biomedical technology that isolates fetal and tumor cells from liquid biopsies, enhancing non-invasive prenatal testing and the monitoring of gynecological diseases. This technology provides healthcare professionals with precise tools for improved prognostic and treatment options, addressing the need for safer diagnostic methods in women's and fetal health.
Funding
$700K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for prenatal testing and monitoring gynecological diseases often involve invasive procedures that pose risks to both the mother and the fetus. Obtaining fetal and tumor cells for analysis can be challenging, hindering early and accurate diagnosis.
Solution
Bioliquid is developing technology to isolate fetal and tumor cells from liquid biopsies, offering a non-invasive approach to prenatal testing and monitoring of gynecological diseases. Their focus is on creating tools that improve the accuracy of non-invasive prenatal tests, as well as the prognosis, treatment, and monitoring of gynecological diseases. The core technology aims to provide healthcare professionals with a safer and more precise method for early disease detection and personalized treatment strategies. Bioliquid's "Miracle" device is designed for non-invasive liquid biopsies to diagnose prenatal diseases and placental disorders.
Target Audience
The primary target audience includes healthcare professionals specializing in prenatal care, gynecology, and oncology, as well as clinical laboratories and research institutions focused on women's and fetal health.
Features
- Isolation of fetal cells from maternal blood samples
- Isolation of tumor cells from liquid biopsies
- Development of non-invasive prenatal tests
- Tools for prognosis and treatment monitoring of gynecological diseases
- "Miracle" device for diagnosing prenatal diseases and placental disorders
- Aptamer-based cell isolation